MET and neoplasm: Furthermore, REGN5093-M114 effectively reduced tumor growth in EGFR-mutant NSCLC cases with PTEN loss or c-MET-Y1230C mutation, even in cases of prior progression on osimertinib and savolitinib treatment (111).